Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

22 juin 2020 09h00 HE | Source: Acepodia USA

Acepodia Presents Preclinical Data on its Lead NK Cell Therapy Candidate ACE1702 at 2020 AACR Virtual Meeting II

Preclinical data demonstrate anti-tumor activity with ACE1702 in vitro and in vivo SAN FRANCISCO and TAIPEI, Taiwan, June 22, 2020 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing...
08 juin 2020 07h30 HE | Source: Acepodia USA

Acepodia Provides Corporate Update and Unveils New Preclinical Allogeneic NK Cell Therapy Pipeline Candidates at BIO Digital 2020

First clinical trial site for ACE1702 initiated, with clinical data expected in Q4 2020Investigational New Drug clearance expected for ACE1755 in Q1 2021 Pipeline expansion incorporating CAR...
09 janv. 2020 07h30 HE | Source: Acepodia USA

Acepodia Announces FDA Clearance of IND for its NK Cell Therapy Drug Candidate ACE1702 to Treat Patients with HER2-expressing Solid Tumors

SAN FRANCISCO and TAIPEI, Taiwan, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing cancer immunotherapy based on its novel ACC™ (Antibody Cell-Conjugation) technology...